AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS

被引：0

作者：

Mellinghoff, Ingo K. ^{[1
]}

Touat, Mehdi ^{[2
]}

Maher, Elizabeth ^{[3
]}

DeLaFuente, Macarena ^{[4
]}

Cloughesy, Timothy F. ^{[5
]}

Holdhoff, Matthias ^{[6
]}

Cote, Gregory ^{[7
]}

Burris, Howard ^{[8
]}

Janku, Filip ^{[9
]}

Huang, Raymond ^{[7
]}

Young, Robert ^{[1
]}

Ellingson, Benjamin ^{[5
]}

Auer, Julia ^{[10
]}

Liu, Hua ^{[10
]}

Hurov, Jonathan ^{[10
]}

Yen, Katherine ^{[10
]}

Agresta, Sam ^{[10
]}

Attar, Eyal ^{[10
]}

Pandya, Susan ^{[10
]}

Wen, Patrick Y. ^{[7
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[2] Inst Gustave Roussy, Paris, France

[3] UT Southwestern, Dallas, TX USA

[4] Univ Miami, Miami, FL USA

[5] Univ Calif Los Angeles, Los Angeles, CA USA

[6] Johns Hopkins Univ, Baltimore, MD USA

[7] Dana Farber Harvard Canc Ctr, Boston, MA USA

[8] Sarah Cannon Res Inst, Nashville, TN USA

[9] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[10] Agios Pharmaceut, Cambridge, MA USA

来源：

NEURO-ONCOLOGY | 2016年 / 18卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

ACTR-46

引用

页码：12 / 12

页数：1

共 50 条

[1] AG-120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION
Mellinghoff, Ingo K.
Touat, Mehdi
Maher, Elizabeth
De la Fuente, Macarena
Cloughesy, Timothy F.
Holdhoff, Matthias
Cote, Gregory M.
Burris, Howard
Janku, Filip
Huang, Ray
Young, Robert J.
Ellingson, Benjamin
Nimkar, Tara
Jiang, Liewen
Ishii, Yuko
Choe, Sung
Fan, Bin
Steelman, Lori
Yen, Katharine
Bowden, Chris
Pandya, Susan
Wen, Patrick Y.
NEURO-ONCOLOGY, 2017, 19 : 10 - 11
[2] Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
Popovici-Muller, Janeta
Lemieux, Rene M.
Artin, Erin
Saunders, Jeffrey O.
Salituro, Francesco G.
Travins, Jeremy
Cianchetta, Giovanni
Cai, Zhenwei
Zhou, Ding
Cui, Dawei
Chen, Ping
Straley, Kimberly
Tobin, Erica
Wang, Fang
David, Muriel D.
Penard-Lacronique, Virginie
Quivoron, Cyril
Saada, Veronique
De Botton, Stephane
Gross, Stefan
Dang, Lenny
Yang, Hua
Utley, Luke
Chen, Yue
Kim, Hyeryun
Jin, Shengfang
Gu, Zhiwei
Yao, Gui
Luo, Zhiyong
Lv, Xiaobing
Fang, Cheng
Yan, Liping
Olaharski, Andrew
Silverman, Lee
Biller, Scott
Su, Shin-San M.
Yen, Katharine
ACS MEDICINAL CHEMISTRY LETTERS, 2018, 9 (04): : 300 - 305
[3] PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION
Mellinghoff, Ingo
Penas-Prado, Marta
Peters, Katherine
Cloughesy, Timothy
Burris, Howard
Maher, Elizabeth
Janku, Filip
Cote, Gregory
De La Fuente, Macarena
Clarke, Jennifer
Steelman, Lori
Le, Kha
Xu, Huansheng
Sonderfan, Alison
Hummel, Diana
Schoenfeld, Steven
Yen, Katharine
Pandya, Shuchi
Wen, Patrick
NEURO-ONCOLOGY, 2018, 20 : 18 - 18
[4] Discovery of AG-120: A first-in-class inhibitor of IDH1 mutant enzymes for the treatment of cancers harboring IDH1 mutations
Popovici-Muller, Janeta
Lemieux, Rene
Saunders, Jeffrey
Salituro, Francesco
Yen, Katharine
Straley, Kimberly
Tobin, Erica
Wang, Fang
Gross, Stefan
Artin, Erin
Dang, Lenny
Yang, Hua
Utley, Luke
Chen, Yue
Olaharski, Andrew
Silverman, Lee
Agresta, Sam
Su, Michael
Biller, Scott
ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
[5] Mutant IDH1 and seizures in patients with glioma
Chen, Hao
Judkins, Jonathon
Thomas, Cheddhi
Wu, Meijing
Khoury, Laith
Benjamin, Carolina G.
Pacione, Donato
Golfinos, John G.
Kumthekar, Priya
Ghamsari, Farhad
Chen, Li
Lein, Pamela
Chetkovich, Dane M.
Snuderl, Matija
Horbinski, Craig
NEUROLOGY, 2017, 88 (19) : 1805 - 1813
[6] IDH-mutant glioma: A new IDH1 inhibitor moves forward
Miller, Julie J.
Arrillaga-Romany, Isabel
NEURO-ONCOLOGY, 2023, 25 (02) : 337 - 338
[7] THE IDH1 MUTANT INHIBITOR AG-120 SHOWS STRONG INHIBITION OF 2-HG PRODUCTION IN AN ORTHOTOPIC IDH1 MUTANT GLIOMA MODEL IN VIVO
Nicolay, Brandon
Narayanaswamy, Rohini
Aguado, Elia
Nagaraja, Raj
Murtie, Josh
Liu, Guowen
Ishii, Yuko
NEURO-ONCOLOGY, 2017, 19 : 86 - 86
[8] Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial
Mellinghoff, Ingo K.
Penas-Prado, Marta
Peters, Katherine B.
Burris, Howard A.
Maher, Elizabeth A.
Janku, Filip
Cote, Gregory M.
de la Fuente, Macarena, I
Clarke, Jennifer L.
Ellingson, Benjamin M.
Chun, Saewon
Young, Robert J.
Liu, Hua
Choe, Sung
Lu, Min
Le, Kha
Hassan, Islam
Steelman, Lori
Pandya, Shuchi S.
Cloughesy, Timothy F.
Wen, Patrick Y.
CLINICAL CANCER RESEARCH, 2021, 27 (16) : 4491 - 4499
[9] CLINICAL SAFETY AND ACTIVITY OF AG-120, A FIRST-IN-CLASS, POTENT INHIBITOR OF THE IDH1 MUTANT PROTEIN, IN A PHASE 1 STUDY OF PATIENTS WITH ADVANCED IDH1-MUTANT HEMATOLOGIC MALIGNANCIES
de Botton, S.
Pollyea, D. A.
Stein, E. M.
DiNardo, C.
Fathi, A. T.
Roboz, G. J.
Collins, R.
Swords, R. T.
Flinn, I.
Altman, J. K.
Tallman, M. S.
Kantarjian, H.
Colby, K.
Fan, B.
Goldwasser, M.
Prahl, M.
Agresta, S.
Stone, R. M.
HAEMATOLOGICA, 2015, 100 : 214 - 215
[10] Mutant IDH1 Promotes Glioma Formation In Vivo
Philip, Beatrice
Yu, Diana X.
Silvis, Mark R.
Shin, Clifford H.
Robinson, James P.
Robinson, Gemma L.
Welker, Adam E.
Angel, Stephanie N.
Tripp, Sheryl R.
Sonnen, Joshua A.
VanBrocklin, Matthew W.
Gibbons, Richard J.
Looper, Ryan E.
Colman, Howard
Holmen, Sheri L.
CELL REPORTS, 2018, 23 (05): : 1553 - 1564

← 1 2 3 4 5 →